SHANGHAI, China, October 29, 2025 (EZ Newswire) -- WuXi AppTec, opens new tab, a global contract research, development, and manufacturing organization (CRDMO), recently hosted its 2025 Investor Day, showcasing the company's continued leadership as a trusted partner in global drug discovery, development, and manufacturing. The comprehensive presentation highlighted WuXi AppTec's sustained high-growth trajectory, market-leading position, and expanding capabilities across its integrated CRDMO platform.
WuXi Chemistry CRDMO Platform Drives Significant Growth
WuXi AppTec's chemistry division, operating as a global CRDMO platform, reported exceptional performance with revenue reaching $2.3 billion in the first half of 2025, representing a 33.5% year-over-year increase. The integrated platform serves 2,550 clients across 15 global sites with 23,445 employees as of June 30, 2025, reinforcing WuXi AppTec's position as a trusted partner to pharmaceutical and biotech innovators worldwide.
"Our CRDMO business model continues to drive sustained high growth by integrating drug discovery, development, and manufacturing into a single open-access platform," said Dr. Minzhang Chen, co-CEO of WuXi AppTec. "This integrated approach continues to prove it reduces drug development timelines and helps advance breakthrough medicines for patients globally."
The company's small molecule pipeline has grown to over 440,000 compounds, with 412 new molecules added to the development and manufacturing pipeline in the first half of 2025 alone. Notably, WuXi AppTec supported eight small molecules approved by the U.S. Food and Drug Administration between 2024 and the first half of 2025, demonstrating the company's critical role in bringing innovative therapies to patients.
WuXi TIDES: Unlocking Significant Growth in Next-Generation Modalities
WuXi AppTec's TIDES (oligonucleotides, peptides, and conjugates) business continues unprecedented growth, with revenue reached $0.71 billion in the first half of 2025, and expected growth over 80% year over year in full year revenue. The division has established itself as a key player across the CRDMO value chain, helping deliver vital therapeutics to patients worldwide.
Dr. Minzhang Chen highlighted the division's expansion: "WuXi TIDES is driving more complex oligonucleotide and peptide conjugate therapeutics faster to patients.” In the third quarter of 2025, its total reactor volume of solid-phase peptide synthesizers exceeds 100,000 liters, supporting the growing demand for next-generation therapies."
The global peptide therapeutics market is projected to reach $160.3 billion by 2030, while the oligonucleotide therapeutics market is expected to grow to $31.5 billion by 2030, positioning WuXi TIDES for continued substantial growth.
Operational Excellence and Digital Innovation
WuXi AppTec demonstrated its commitment to operational excellence through "WuXi Speed," achieving faster plant construction and ramp-up times. The company has reduced plant ramp-up periods from 22.6 months in 2017 to just 2.4 months in 2024, accelerating products to patients through proven operational playbooks.
The company has implemented comprehensive digital systems with over 90 application systems covering all aspects of operations, achieving "smart" operations that enhance efficiency and maintain quality standards. This digital transformation supports WuXi AppTec's zero critical FDA observations record in 2024 and reinforces its position as a trusted partner meeting the global regulatory standards.
Global Reach and Regional Growth
WuXi AppTec's global footprint continues to expand, with strong revenue growth across key regions in the first half of 2025:
North America: 38.4% year-over-year growth
Europe: 9.2% year-over-year growth
Japan, Korea, and rest of world: 7.6% year-over-year growth
The company's diversified geographic presence across Asia, Europe, and North America ensures resilient operations and enables faster, compliant market access for therapies worldwide through multi-jurisdictional regulatory expertise spanning FDA, EMA, and NMPA guidelines.
Commitment to Sustainability and Global Health
Building on its 25-year legacy as a trusted partner, WuXi AppTec continues its commitment to global health and sustainability. The company has achieved carbon neutrality across discovery operations and remains committed to net-zero emissions by 2030. Compared to its 2020 baseline, the company has reduced water usage intensity by over 36% last year.
About WuXi AppTec
Building on 25 years as a trusted global CRDMO partner, accelerating regulatory approvals and powering next-generation therapies across the innovation spectrum, WuXi AppTec remains dedicated to enabling breakthrough medicines and global health.
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (contract research, development, and manufacturing organization) platform. We are privileged to work alongside nearly 6,000 partners across more than 30 countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients — one collaboration at a time.
Learn more at wuxiapptec.com, opens new tab.
Share this post